Indy

Market narrative

Read the headlines around the signals.

Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.

Latest newsfilecorp.com · about 8 hours ago

Kaplan Fox Notifies Cogent Communications Holdings, Inc. (CCOI) Investors of a Securities Class Action Deadline on September 21, 2026

New York, New York--(Newsfile Corp. - August 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Cogent Communications Holdings, Inc. ("Cogent" or the "Company") (NASDAQ: CCOI) on behalf of investors that purchased or otherwise acquired Cogent securities between February 29, 2024 and May 1, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Cogent and have suffered losses, you may CLICK HERE to contact us.

Read full story ↗ Research CCOI

Stocks

More recent coverage

Page 3
AMAT seekingalpha.com · about 8 hours ago

Applied Materials: July Purged Positioning, Not The Thesis

Applied Materials (AMAT) delivered record Q2 FY2026 revenue of $7.91B (+11% Y/Y) and non-GAAP EPS of $2.86 (+20% Y/Y). Management raised CY2026 equipment growth guidance to 30%+, with improved order visibility and strong DRAM and AGS segment performance. Despite a ~40% drawdown from highs, fundamentals remain robust, and the recent correction is attributed to sector positioning rather than company weakness.

Read source ↗
MDCX proactiveinvestors.com · about 8 hours ago

Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI

Medicus Pharma (NASDAQ:MDCX) earlier this week announced that the US Food and Drug Administration (FDA) has cleared the company's Phase 2b registration-enabling clinical trial for SkinJect in patients with Gorlin syndrome, representing an important regulatory milestone for its lead investigational asset. Speaking with Proactive, CEO Raza Bokhari said the FDA had approved the company's proposed study following discussions and feedback, allowing Medicus Pharma (NASDAQ:MDCX) to move ahead with a crossover registration study involving up to 50 patients.

Read source ↗
FUTU newsfilecorp.com · about 8 hours ago

FUTU DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Futu Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - FUTU

New York, New York--(Newsfile Corp. - August 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Futu Holdings Limited (NASDAQ: FUTU) between May 24, 2023 and May 27, 2026, inclusive (the "Class Period"), of the important August 25, 2026 lead plaintiff deadline. SO WHAT: If you purchased Futu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read source ↗
SKW businesswire.com · about 8 hours ago

Skyworks Solutions Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Skyworks Solutions, Inc. - SKW

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Skyworks Solutions, Inc. (NasdaqGS: SKW) (“Skyworks” or the “Company”). On February 5, 2025, the Company announced its financial results for the first quarter of fiscal year 2025, disclosing lower-than anticipated revenue guidance for the second quarter of fiscal year 202.

Read source ↗
COLL seekingalpha.com · about 8 hours ago

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.

Read source ↗
BE fool.com · about 8 hours ago

Is Bloom Energy in Its Nvidia Moment?

Bloom Energy reported stellar results for the second quarter of 2026, surpassing $1 billion in quarterly revenue for the first time. The energy technology company also reported a profit of $196.2 million.

Read source ↗
MSFT youtube.com · about 8 hours ago

Lisa Martin: Big Tech Earnings & MSFT Role as a Hyperscaler Benchmark

Lisa Martin breaks down this quarter's Big Tech earnings, explaining why investor reactions are driven as much by expectations and timing as the results themselves. She discusses how hyperscalers are being held to a higher standard, why Microsoft's (MSFT) earnings helped calm concerns that emerged after Alphabet's (GOOGL) report, and how Microsoft has become a benchmark for both cloud computing and AI.

Read source ↗
XLV fool.com · about 8 hours ago

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.58% for Invesco Biotechnology & Genome ETF Invesco Biotechnology & Genome ETF holds a concentrated basket of 30 biotech firms, whereas State Street Health Care Select Sector SPDR ETF provides exposure to 60 broad healthcare companies State Street Health Care Select Sector SPDR ETF has experienced a shallower maximum drawdown and lower volatility than Invesco Biotechnology & Genome ETF over the last five years

Read source ↗
MSFT businesswire.com · about 8 hours ago

Microsoft Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Microsoft Corporation - MSFT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Microsoft Corporation (“Microsoft” or the “Company”) (NasdaqGS: MSFT). In recent years, Microsoft's cloud computing platform, known as Azure, has been its main growth driver providing customers with computing, networking, storage, mobile and web application services, arti.

Read source ↗
SCHF seekingalpha.com · about 9 hours ago

SCHF: Global Markets Continue To Entice Me

Schwab International Equity ETF (SCHF) seeks to track the FTSE Developed ex US Index, offering broad international developed market exposure. SCHF's significant allocation to Japanese equities is supported by robust wage growth, moderate inflation, and strong corporate buybacks, though valuations are above historical averages. I am cautious on US tech due to aggressive capex and euphoria, preferring to allocate new capital to SCHF's international mix for balanced global exposure.

Read source ↗
MU fool.com · about 9 hours ago

Where Will Micron Stock Be in 2030?

Micron's fiscal third-quarter revenue of $41.5 billion exceeded any full fiscal year in company history. Management guided for about $50 billion of revenue in the current quarter at an 86% gross margin.

Read source ↗
EDV seekingalpha.com · about 9 hours ago

EDV: A 22-Basis-Point Move Can Erase A Year Of Income

The Vanguard Extended Duration Treasury ETF (EDV) offers a 5.38% SEC yield but exposes investors to extreme duration risk. EDV's yield provides minimal protection; a 22-basis-point rise in long-term yields can offset a full year of income. EDV's upside depends on a significant decline in long-term yields, not just Fed rate cuts; real yields and fiscal dynamics are key risks.

Read source ↗
FHLC fool.com · about 9 hours ago

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit?

Fidelity MSCI Health Care Index ETF carries a significantly lower expense ratio of 0.08% compared to 0.38% for iShares U.S. Healthcare ETF Fidelity MSCI Health Care Index ETF provides broader exposure with 334 holdings, while iShares U.S. Healthcare ETF is more concentrated with 100 positions Both funds exhibit similar risk profiles with five-year maximum drawdowns near 18% and nearly identical beta measurements

Read source ↗
FOX proactiveinvestors.com · about 9 hours ago

Fox Tungsten CEO provides update on drill program at British Columbia project - ICYMI

Fox Tungsten Ltd (TSX-V:FOXT, OTC:HPYCF, FRA:1HC) CEO Steve Gray talked with Proactive about the company's fully funded 20,000-metre drill program at the Fox Project in British Columbia's Cariboo region, providing an update on encouraging early-stage drilling observations before assay results are available. Proactive: Welcome back inside our Proactive newsroom.

Read source ↗
← Newer
Older →